Concepedia

Sharon Friedlander

SF

Statistics

Publications

14

Citations

1.1K

H-Index

12

Active since

2009

Affiliations

Karyopharm Therapeutics (United States)(Current)

Takeda (United States)

Hackensack University Medical Center

Vanderbilt University

Cornell University

Sharon Friedlander is an author at Karyopharm Therapeutics (United States) specializing in medicine, oncology, and pharmacology.

Publications per year

2009–2022

14

Publications

14

Context-Dependent Transformation of Adult Pancreatic Cells by Oncogenic K-Ras

Sharon Friedlander, Gerald C. Chu, Eric L. Snyder et al. · Europe PMC (PubMed Central) · 2009 · 329 citations

, , +12

Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma

Mrinal M. Gounder, Alona Zer, William D. Tap et al. · Journal of Clinical Oncology · 2016 · 165 citations · Full text

, , +16

Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma

John Kuruvilla, Michael R. Savona, Rachid Baz et al. · Blood · 2017 · 157 citations · Full text

, , +11

Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error

Michail Shipitsin, Caleb Small, Sangita Choudhury et al. · British Journal of Cancer · 2014 · 143 citations · Full text

, , +17

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML

Lionel Adès, Larisa Girshova, Vadim Doronin et al. · Blood Advances · 2022 · 121 citations · Full text

, , +14

1–5 of 14